Oxytocin free acid(Synonyms: 9-Deamidooxytocin)

Oxytocin free acid;(Synonyms: 9-Deamidooxytocin)

Oxytocin free acid (9-Deamidooxytocin) 是催产素的类似物,其 9 位的甘氨酸残基被甘氨酸残基取代。Oxytocin 是一种多效性肽类激素,对一般健康、适应、发育、生殖和社会行为有广泛的影响。

Oxytocin free acidamp;;(Synonyms: 9-Deamidooxytocin)

Oxytocin free acid Chemical Structure

CAS No. : 4248-64-0

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

生物活性

Oxytocin free acid (9-Deamidooxytocin) is an analog of oxytocin in which the glycinamide residue at position 9 in oxytocin has been replaced by a glycine residue. Oxytocin is a pleiotropic, peptide hormone with broad implications for general health, adaptation, development, reproduction, and social behavior[1][2].

分子量

1008.17

Formula

C43H65N11O13S2

CAS 号

4248-64-0

Sequence Shortening

CYIQNCPLG (Disulfide bridge:Cys1-Cys6)

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Ferrier BM, et al. 9-Deamidooxytocin, an analog of the hormone containing a glycine residue in place of the glycinamide residue. J Med Chem. 1966;9(1):55-57.

    [2]. Carter CS, Kenkel WM, MacLean EL, et al. Is Oxytocin “Nature’s Medicine”?. Pharmacol Rev. 2020;72(4):829-861.

Ezatiostat(Synonyms: TER199(free base) TLK199)

Ezatiostat;(Synonyms: TER199(free base); TLK199) 纯度: ge;96.0%

Ezatiostat (TER199 free base; TLK199) 是一种谷胱甘肽的三肽类似物,也是一种选择性的口服活性的谷胱甘肽 S-转移酶 P1-1 (GSTP1) 抑制剂。Ezatiostat 通过抑制 GSTP1 导致 JNK 激活。Ezatiostat 刺激淋巴细胞生成和骨髓祖细胞增殖,可用于骨髓增生异常综合症 (MDS) 的研究。

Ezatiostatamp;;(Synonyms: TER199(free base);  TLK199)

Ezatiostat Chemical Structure

CAS No. : 168682-53-9

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg) ; Apply now ;
10;mM;*;1 mL in DMSO ¥867 In-stock
5 mg ¥744 In-stock
10 mg ¥1256 In-stock
50 mg ¥3720 In-stock
100 mg ¥6324 In-stock
200 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Ezatiostat 相关产品

bull;相关化合物库:

  • Drug Repurposing Compound Library Plus
  • Clinical Compound Library Plus
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • Metabolism/Protease Compound Library
  • Anti-Cancer Compound Library
  • Clinical Compound Library
  • Peptidomimetic Library
  • Drug Repurposing Compound Library
  • Antioxidants Compound Library
  • Oxygen Sensing Compound Library
  • Anti-COVID-19 Compound Library
  • Endoplasmic Reticulum Stress Compound Library
  • Orally Active Compound Library
  • Peptide Library

生物活性

Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment[1][2].

IC50 Target

Glutathione S-transferase P1-1 (GSTP1)[1]

体外研究
(In Vitro)

Ezatiostat causes dissociation of the enzyme from the jun-N-terminal kinase/c-Jun (JNK/JUN) complex, leading to JNK activation by phosphorylation. The therapeutic action of ezatiostat appears to include both proliferation of normal myeloid progenitors as well as apoptosis of the malignant clone[1].
Selection of a resistant clone of an HL60 tumor cell line through chronic exposure to Ezatiostat (TLK199) results in cells with elevated activities of c-Jun NH2 terminal kinase (JNK1) and ERK1/ERK2, and allowes the cells to proliferate under stress conditions that induced high levels of apoptosis in the wild type cells[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Administration of Ezatiostat (TLK199), stimulates both lymphocyte production and bone marrow progenitor (colony-forming unit-granulocyte macrophage) proliferation, but only in glutathione S-transferase P1-1 (GSTP1+/+) and not in GSTP1-/- animals[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

分子量

529.65

Formula

C27H35N3O6S

CAS 号

168682-53-9

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
溶解性数据
In Vitro:;

DMSO : ≥ 100 mg/mL (188.80 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 1.8880 mL 9.4402 mL 18.8804 mL
5 mM 0.3776 mL 1.8880 mL 3.7761 mL
10 mM 0.1888 mL 0.9440 mL 1.8880 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液,再依次添加助溶剂:

——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用; 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂:;10% DMSO ;; 40% PEG300 ;; 5% Tween-80 ;; 45% saline

    Solubility: ≥ 2.75 mg/mL (5.19 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (5.19 mM,饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠,完全溶解于 100 mL ddH₂O 中,得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂:;10% DMSO ;; 90% (20% SBE-β-CD in saline)

    Solubility: 2.75 mg/mL (5.19 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.75 mg/mL (5.19 mM) 的均匀悬浊液,悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中,再用生理盐水定容至 10 mL,完全溶解,澄清透明
  • 3.

    请依序添加每种溶剂:;10% DMSO ;; 90% corn oil

    Solubility: ≥ 2.75 mg/mL (5.19 mM); Clear solution

    此方案可获得 ≥ 2.75 mg/mL (5.19 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例,取 100 μL 27.5 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。

*以上所有助溶剂都可在 MCE 网站选购。
参考文献
  • [1]. Galili N, et al. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome. J Hematol Oncol. 2012 May 6;5:20

    [2]. Ruscoe JE, et al. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther. 2001 Jul;298(1):339-45.

Direct Black 38 free acid(Synonyms: Chlorazol Black E free acid Ferristatin II C.I. 30235 free acid)

Direct Black 38 free acid;(Synonyms: Chlorazol Black E free acid; Ferristatin II; C.I. 30235 free acid)

Direct Black 38 free acid 是一种多聚磺化染料。Direct Black 38 free acid 促进转铁蛋白受体-1 (transferrin receptor-1) 在体内外的降解。

Direct Black 38 free acidamp;;(Synonyms: Chlorazol Black E free acid;  Ferristatin II; C.I. 30235 free acid)

Direct Black 38 free acid Chemical Structure

CAS No. : 22244-14-0

规格 是否有货
100 mg ; 询价 ;
250 mg ; 询价 ;
500 mg ; 询价 ;

* Please select Quantity before adding items.

Direct Black 38 free acid 的其他形式现货产品:

Direct Black 38

生物活性

Direct Black 38 free acid is a polysulphonated dye. Direct Black 38 free acid promotes degradation of transferrin receptor-1 in vitro and in vivo[1].

分子量

737.76

Formula

C34H27N9O7S2

CAS 号

22244-14-0

中文名称

直接黑 38 游离酸

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

参考文献
  • [1]. Beije B. Induction of unscheduled DNA synthesis in liver and micronucleus in bone marrow of rats exposed in vivo to the benzidine-derived azo dye, Direct Black 38. Mutat Res. 1987 Apr;187(4):227-34.

    [2]. Byrne SL, et al. Ferristatin II promotes degradation of transferrin receptor-1 in vitro and in vivo. PLoS One. 2013 Jul 23;8(7):e70199.

Cyclosporin A-Derivative 1 Free base

Cyclosporin A-Derivative 1 Free base; 纯度: 99.29%

Cyclosporin A-Derivative 1 (Free base) 是环孢菌素 A 衍生的结晶中间体,来自专利 WO 2013167703 A1。Cyclosporin A 是一种免疫抑制剂,能够与亲环蛋白结合并抑制钙调磷酸酶。

Cyclosporin A-Derivative 1 Free baseamp;;

Cyclosporin A-Derivative 1 Free base Chemical Structure

CAS No. : 286852-20-8

规格 价格 是否有货 数量
1 mg ¥1500 In-stock
5 mg ¥3500 In-stock
10 mg ; 询价 ;
50 mg ; 询价 ;

* Please select Quantity before adding items.

Cyclosporin A-Derivative 1 Free base 相关产品

bull;相关化合物库:

  • Bioactive Compound Library Plus
  • Peptide Library

生物活性

Cyclosporin A-Derivative 1 (Free base) is a crystalline intermediate derived from the opening of cyclosporin A extracted from patent WO 2013167703 A1. Cyclosporin A is an immunosuppressive agent which can bind to the cyclophilin and inhibit calcineurin.

体外研究
(In Vitro)

Cyclosporin A-Derivative 1 is a non-immunosuppressive Cyclosporin A derivative. The cyclosporin is acylated on the butenyl-methyl-threonine side chain and then subjected to a ring-opening reaction (the ring opens between the sarcosine and the N-methyl-leucine residues). Cyclosporin A-Derivative 1 is a linear peptide intermediate[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

1276.69

Formula

C65H117N11O14

CAS 号

286852-20-8

Sequence

Leu-Val-Leu-Ala-{d-Ala}-Leu-Leu-Val-{Aaa}-{Abu}-{Sar}

Sequence Shortening

LVLA-{d-Ala}-LLV-{Aaa}-{Abu}-{Sar}

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式
Powder -80deg;C 2 years
-20deg;C 1 year
In solvent -80deg;C 6 months
-20deg;C 1 month
参考文献
  • [1]. Fabrice Gallou, et al. Process for the manufacture of cyclic undecapeptides. WO 2013167703 A1.